VolitionRX Osake

VolitionRX EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä VolitionRX (VNRX) 4.8.2026 päivämäärällä on −25,72 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −34,58 M USD — muutos −25,61 % (korkeampi).

EBITDA

−25,72 MUSD

YoY

−25,61%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä VolitionRX on 2026 −25,72 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä VolitionRX oli 2025 −34,58 M USD. Se laskee −25,61% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

VolitionRX Osakeanalyysi

Mitä VolitionRX tekee? VolitionRX Ltd was founded in 2010 with headquarters in Austin, Texas. It is a multinational life science company specializing in the discovery of cancer and other disease markers. The company's mission is to improve the quality of life for millions of people worldwide through the development of pain diagnostic systems. History VolitionRX began as a collaboration between scientists Professor Avraham Rasooly from the University of California and Professor David Kroll from North Carolina State University. The two professors were searching for a more effective diagnostic method for cancer and eventually co-founded VolitionRX in 2010. Initially, the company focused on developing diagnostic tests for stomach and colorectal cancer. Business model VolitionRX is a research-based company that specializes in the development of diagnostic and testing systems for cancer. The company works closely with leading cancer experts and scientific institutions to achieve groundbreaking research results. The goal is to develop innovative diagnostic methods that enable doctors to detect cancer faster and more effectively. Divisions VolitionRX is divided into three main areas: diagnostic tests, research and development, and partner and customer relations. Diagnostic tests VolitionRX offers a variety of diagnostic tests for cancer and other diseases. The tests are based on nucleosomics technology, which allows for analysis of cellular DNA. VolitionRX has developed various tests for colorectal cancer, lung cancer, pancreatic cancer, and other types of cancer, and is working on new tests for other conditions. Research and development VolitionRX continuously invests in research and development of new diagnostic methods for cancer and other diseases. The company collaborates closely with leading scientific institutions and cancer experts to develop innovative solutions for cancer diagnostics. Partner and customer relations VolitionRX works with a range of partners to distribute its diagnostic tests worldwide. The company has partnerships with various diagnostic laboratories and medical institutions to make its tests available to a wider target audience. Products VolitionRX offers a variety of products for the diagnosis of cancer and other diseases. These include: 1. NuQ blood tests for the diagnosis of colorectal cancer and other types of cancer. 2. Nucleosomics technology for analysis of cellular DNA for early cancer detection. 3. Software for data analysis from medical tests. Future prospects VolitionRX aims to further improve its technology for cancer diagnosis in order to save lives and improve the quality of life for people worldwide. The company's future prospects are promising as the demand for fast and effective cancer diagnostic methods continues to increase due to the rising number of cancer cases worldwide. VolitionRX on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset VolitionRX osakkeesta

Yhtiön VolitionRX EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −25,72 M USD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä VolitionRX muuttui arvosta −34,58 M USD arvoon −25,72 M USD, mikä edustaa −25,61 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) VolitionRX:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n VolitionRX historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — VolitionRX

Kaikki tunnusluvut — VolitionRX